RAND Drug Policy Research Center, 1776 Main Street, Santa Monica, CA 90401, United States of America.
RAND, 1200 South Hayes Street, Arlington, VA 22202-5050, United States of America.
J Subst Abuse Treat. 2021 May;124:108288. doi: 10.1016/j.jsat.2021.108288. Epub 2021 Jan 13.
During the COVID-19 pandemic, opioid treatment programs (OTPs) in the U.S. were granted new flexibility in methadone dispensing and the use of telemedicine. To explore the impact of the pandemic and accompanying policy changes on service delivery, we asked OTP clinicians about changes in care patterns and perceptions of impacts on access and quality.
In May-June 2020, we completed semistructured telephone interviews with 20 OTP clinicians (physicians, physician assistants, and nurse practitioners) from 13 U.S. states. The study recruited participants through Medscape, an online platform where clinicians access clinical content. We used rapid thematic analysis, a qualitative approach, to summarize participants' expressed views related to the research objectives.
Clinicians identified a range of changes to methadone and ancillary service delivery as a result of COVID-19. Most clinicians reported that OTPs were prescribing more take-home doses of methadone and providing psychosocial services and medication management via telemedicine. Many also reported reducing the frequency of urine toxicology screening and accepting fewer new patients. While some clinicians expressed support for the increased flexibility around dosing and use of telemedicine, others expressed concern about increased risk of medication diversion and overdose. Clinicians reported several advantages and disadvantages of the changes due to the pandemic and that continued reimbursement would be required to maintain telemedicine services.
The COVID-19 pandemic dramatically altered the delivery of methadone treatment in the U.S. This study's findings suggest that OTPs may have reduced their methadone treatment during the early months of the pandemic and that the flexibilities that policy changes offered may not have resulted in changes in care delivery for all patients. Careful consideration and additional analysis should inform which changes OTPs should maintain long-term.
在 COVID-19 大流行期间,美国的阿片类药物治疗计划(OTP)在美沙酮配药和使用远程医疗方面获得了新的灵活性。为了探索大流行及其伴随的政策变化对服务提供的影响,我们询问了 OTP 临床医生有关护理模式变化以及对获取和质量影响的看法。
在 2020 年 5 月至 6 月期间,我们通过 Medscape 完成了对来自美国 13 个州的 20 名 OTP 临床医生(医生、医生助理和护士从业者)的半结构化电话访谈。该研究通过 Medscape 招募参与者,Medscape 是一个临床医生获取临床内容的在线平台。我们使用快速主题分析(一种定性方法)总结参与者对研究目标表达的观点。
临床医生确定了由于 COVID-19 而导致美沙酮和辅助服务提供方式的一系列变化。大多数临床医生报告说,OTP 正在开更多的美沙酮口服剂量,并通过远程医疗提供心理社会服务和药物管理。许多人还报告说减少了尿液毒理学筛查的频率,并减少了新患者的数量。虽然一些临床医生对增加剂量和使用远程医疗的灵活性表示支持,但也有一些临床医生对药物滥用和过量的风险增加表示担忧。临床医生报告了由于大流行而导致的变化的一些优缺点,并且需要继续报销才能维持远程医疗服务。
COVID-19 大流行极大地改变了美国美沙酮治疗的提供方式。本研究的结果表明,OTP 在大流行的早期可能已经减少了美沙酮治疗,并且政策变化提供的灵活性可能并没有导致所有患者的护理交付方式发生变化。应仔细考虑并进行额外分析,以告知 OTP 应长期维持哪些变化。